Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said on Thursday.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily to increase production.

Key Takeaways Eli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and weight-loss drugs.The company's Alzheimer's drug, Kisunla, was approved by the U.S. Food and Drug Administration last month.